Sugiol
Based on 1 Customer Validation
Sugiol is an abietane diterpenoid, can be isolated from Calocedrus formosana bark. Sugiol has anti-inflammatory activity, could effectively reduce intracellular reactive oxygen species (ROS) production in lipopolysaccharide (LPS)-stimulated macrophages.
For research use only. We do not sell to patients.
- Purity : 99.88%
- CAS No.: 511-05-7
- Formula: C20H28O2
- Molecular Weight:300.44
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
ERK1 |
ERK2 |
p38 MAPK |
JNK1 |
JNK2 |
IL-1β |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
<50 μg/mL
Compound: 4
|
Inhibitory activity against human A549 lung tumor cell proliferation
Inhibitory activity against human A549 lung tumor cell proliferation
|
[PMID: 15808460] |
| A549 | GI50 |
79.8 μM
Compound: 13
|
Cytotoxicity against human A549 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human A549 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| A549 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| BEAS-2B | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| BXPC-3 | GI50 |
36.08 μM
Compound: 13
|
Cytotoxicity against human BxPC3 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human BxPC3 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| HCT-116 | GI50 |
<50 μg/mL
Compound: 4
|
Growth inhibitory activity against human HCT116 colon tumor cell line
Growth inhibitory activity against human HCT116 colon tumor cell line
|
[PMID: 15808460] |
| HL-60 | GI50 |
68.64 μM
Compound: 13
|
Cytotoxicity against human HL60 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human HL60 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| HL-60 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| K562 | IC50 |
6.7 μM
Compound: Sugiol
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 30684866] |
| MCF7 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| MDA-MB-231 | GI50 |
<50 μg/mL
Compound: 4
|
Growth inhibitory activity against human MDA-MB-231 breast tumor cell line
Growth inhibitory activity against human MDA-MB-231 breast tumor cell line
|
[PMID: 15808460] |
| MIA PaCa-2 | IC50 |
17.9 μM
Compound: 10
|
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
|
[PMID: 21775156] |
| MRC5 | GI50 |
>100 μM
Compound: 13
|
Cytotoxicity against human MRC5 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human MRC5 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| NCI-H23 | GI50 |
<50 μg/mL
Compound: 4
|
Growth inhibitory activity against human NCI-H23 lung tumor cell line
Growth inhibitory activity against human NCI-H23 lung tumor cell line
|
[PMID: 15808460] |
| PANC-1 | GI50 |
87.94 μM
Compound: 13
|
Cytotoxicity against human PANC1 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human PANC1 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| PC-3 | GI50 |
>100 μM
Compound: 13
|
Cytotoxicity against human PC3 cells assessed as growth inhibition by WST-8 assay
Cytotoxicity against human PC3 cells assessed as growth inhibition by WST-8 assay
|
[PMID: 24210499] |
| SMMC-7721 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| SW480 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 33978415] |
| SW-620 | GI50 |
<50 μg/mL
Compound: 4
|
Growth inhibitory activity against human SW620 colon tumor cell line
Growth inhibitory activity against human SW620 colon tumor cell line
|
[PMID: 15808460] |
| Vero | IC50 |
24.6 μM
Compound: 2
|
Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 in african green monkey Vero cells
Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 in african green monkey Vero cells
|
[PMID: 25462275] |
| Vero | IC50 |
45.4 μM
Compound: 2
|
Cytotoxicity against african green monkey Vero cells after 72 hrs
Cytotoxicity against african green monkey Vero cells after 72 hrs
|
[PMID: 25462275] |
In Vitro
Sugiol (5-30 μM; 30 min) inhibits TNF-α and proIL-1β/IL-1β protein production in J774A.1 cells[1].
Sugiol (5-30 μM; 30 min) inhibits MAPK activation, suppresses ERK1/2, JUNK1/2, and p38 phosphorylation in LPS-induced J774A.1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:J774A.1 macrophages cells stimulated with LPS
-
Concentration:5 μM, 10 μM, 20 μM, and 30 μM
-
Incubation Time:30 min
-
Result:Completely inhibited ERK1/2 phosphorylation at 30 μM, and effectively inhibited JNK1/2 and p38 phosphorylation.
Chemical Information
-
CAS No. 511-05-7
-
Appearance Solid
-
Molecular Weight 300.44
-
Formula C20H28O2
-
Color White to off-white
-
SMILES
O=C1C2=C(C=C(O)C(C(C)C)=C2)[C@@]3(C)CCCC(C)(C)[C@]3([H])C1
-
Synonyms
(+)-Sugiol; 10-Deoxoxanthoperol
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)